This chemotherapy regimen is commonly used to manage metastatic colorectal cancer (Benson et al., 2014), but also administered to CUP patients with K20+/K7–/CDX2+ IHC signature. The gene discussed is CDX2; the disease is metastatic colorectal cancer.